Carbidopa - Adverse effects
Research News and Information

Saturday, March 20, 2010

Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa.

21 Jul 2009 This open-label phase I trial assessed potential pharmacokinetic interactions between oral levodopa/carbidopa and transdermal rotigotine treatment at steady state. Twenty-four participants with idiopathic restless legs syndrome (12 per group) ... Read more...

Levodopa/carbidopa in the treatment of amblyopia.

27 Feb 2009 PURPOSE: To evaluate the role of levodopa/carbidopa in the treatment of amblyopia. METHODS: Thirty patients with strabismic amblyopia between the ages of 3 and 12 years were part of this double-blind, randomized study. Patients were divided into two ... Read more...

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]

13 Jan 2009 INTRODUCTION: When advanced Parkinson's disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine ... Read more...

Latest indexed articles for 'Carbidopa - Adverse effects'

These are the very latest articles for this heading:

• Drug-induced compulsive behaviors: exceptions to the rule. 30 Aug 2009
• Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. 21 Jul 2009
• Levodopa/carbidopa in the treatment of amblyopia. 27 Feb 2009
• [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety] 13 Jan 2009
• Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. 13 Jan 2009
• Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). 30 Oct 2008
• Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient. 21 Sep 2008
• Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. 20 Aug 2008
• [Stalevo-associated lymphocytic colitis] 6 Apr 2008
• Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy. 30 Dec 2007
• Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. 30 Dec 2007
• Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease. 20 Oct 2007
• Fracture risk associated with parkinsonism and anti-Parkinson drugs. 18 Aug 2007
• Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. 29 Apr 2007
• Skin rash associated with Sinemet does not equal levodopa allergy. 25 Mar 2007
• [Prevention and treatment of fluctuations in patients with Parkinson's disease] 18 Dec 2006
• Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. 26 Nov 2006
• Levodopa can worsen tremor associated with dystonia. 29 Sep 2006
• Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. 30 Aug 2006
• OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease. 30 Aug 2006

See a longer list of these articles.

Technical information about 'Carbidopa'

Definition: An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

Chemical name: Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)-

Registry Number: 38821-49-7

Descriptor UI: D002230

Alternative terms: Carbidopa; Methyldopahydrazine; MK-486; MK 486; MK486; Lodosin; Lodosyn; MK-485; MK 485; MK485; Carbidopa, (R)-Isomer; Carbidopa, (S)-Isomer;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Enzyme Inhibitors; Dopamine Agents;

Tree Number: D02.092.311.200.538.200; D02.442.200;

Online Note: use CARBIDOPA to search METHYLDOPAHYDRAZINE 1973-79 (as Prov 1973-74)

History Note: 80; was METHYLDOPAHYDRAZINE see under HYDRAZINES 1975-79; was METHYLDOPAHYDRAZINE 1973-74 (Prov)